Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Provectus BiopharmaceuticalsPVCT -4.00% EV-to-OCF is -10.72 as of Aug. 03, 2026. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Provectus Biopharmaceuticals ranks better than 72.41% on this metric.
The historical rank and industry rank for Provectus Biopharmaceuticals's EV-to-OCF or its related term are showing as below:
PVCT'
s EV-to-OCF Range Over the Past 10 Years
Min: -11.74 Med: 0 Max: -9.96
Current: -10.72
During the past 13 years, the highest EV-to-OCF of Provectus Biopharmaceuticals was -9.96. The lowest was -11.74. And the median was .
PVCT's EV-to-OCF is ranked better than 72.41% of 1410
companies
in the Biotechnology industry
Industry Median: -3.23
vs PVCT: -10.72
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Provectus Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Provectus Biopharmaceuticals's share price for today is $0.06.
Provectus Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Provectus Biopharmaceuticals EV-to-OCF Related Terms
Provectus Biopharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Provectus Biopharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provectus Biopharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Provectus Biopharmaceuticals's EV-to-OCF falls into.
Provectus Biopharmaceuticals's current Enterprise Value is $27.77 Mil.
Provectus Biopharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals (PVCT) has a EV-to-OCF of -10.72 as of Aug. 03, 2026. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #389 out of 1410 companies in the Biotechnology industry, placing it in the top 27.6%.
Is Provectus Biopharmaceuticals' EV-to-OCF too high?
Provectus Biopharmaceuticals' current EV-to-OCF is -10.72. Based on the distribution chart, Provectus Biopharmaceuticals ranks #389 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint.
How does Provectus Biopharmaceuticals' EV-to-OCF compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #389 out of 1410 companies for EV-to-OCF. This puts Provectus Biopharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Provectus Biopharmaceuticals's current EV-to-OCF is -10.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current EV-to-OCF of -10.72. The current EV-to-OCF is -10.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current EV-to-OCF is -10.72 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PVCT has been successfully added to your 
